<DOC>
	<DOC>NCT00358826</DOC>
	<brief_summary>This is a dose ranging study to compare the effect of VIA-2291 vs. Placebo on various inflammatory biomarkers in patients with recent acute coronary events</brief_summary>
	<brief_title>Study Effect of VIA-2291 on Vascular Inflammation</brief_title>
	<detailed_description>This is a Phase II, randomized, double-blind, placebo-controlled study of the effect of VIA-2291 on atherosclerotic vascular inflammation</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atreleuton</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Female patients are to be of nonchildbearing potential Patient has suffered an ST elevation myocardial infarction (MI), nonST elevation MI, or unstable angina 21 days (Â±3 days) prior to study randomization Patient has documented coronary artery disease Renal insufficiency defined as creatinine &gt;1.5 x upper limit of normal (ULN) Cirrhosis, recent hepatitis, ALT &gt;1.5 x ULN or ALT &gt; 1 x ULN and at least one other liver function test Uncontrolled diabetes mellitus within 1 month prior to study screening Congestive heart failure (CHF) defined by the New York Heart Association as functional Class III or IV Previous coronary artery bypass graft (CABG) surgery Planned additional cardiac intervention Recurrence of ST elevation MI, nonST elevation MI, or unstable angina less than 18 days prior to randomization Current atrial fibrillation, atrial flutter, or frequent premature ventricular contractions Acetaminophen use in any form in the 7 days before enrollment</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>